日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study

来自随机 II 期 BIONIKK 研究的转移性肾细胞癌患者中纳武利尤单抗和伊匹木单抗的暴露-反应关系

Blanchet, Benoit; Puszkiel, Alicja; Jouinot, Anne; Bennamoun, Mostefa; Maillet, Denis; Borchiellini, Delphine; Laguerre, Brigitte; Pannier, Diane; Gross-Goupil, Marine; Chevreau, Christine; Barthélémy, Philippe; Tournigand, Christophe; Coquan, Elodie; Gravis, Gwenaelle; Lepicard, Eve; Fridman, Wolf Herman; Sautes-Fridman, Catherine; Oudard, Stéphane; Sun, Cheng-Ming; Vano, Yann-Alexandre

Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration)

风险分层和治疗获益:预测多西他赛治疗试验中转移性新发激素敏感性前列腺癌男性患者总生存期的模型(STOPCAP 合作组)

Halabi, Susan; Luo, Bin; Yu, Chenxi; Rydzewska, Larysa H M; Roy, Akash; Kim, Hyotae; Godolphin, Peter J; Murphy, Laura; Carducci, Michael A; Gravis, Gwenaëlle; Sfumato, Patrick; Boher, Jean-Marie; James, Nicholas D; Tierney, Jayne F; Page, David; Sweeney, Christopher; Guo, Siyuan

Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum

加速癌症治疗优化:癌症药物论坛的多方利益相关者路线图

Lacombe, Denis; Cardoso Borges, Fábio; Amariutei, Ana E; Booth, Christopher M; Brusselle, Guy; Casolino, Raffaella; Demolis, Pierre; Giuliani, Rosa; Goldstein, Daniel A; Gravis, Gwenaelle; Kaiser, Martin; Korakis, Iphigenie; Radulovic, Momir; Sullivan, Richard; Tombal, Bertrand; Wieseler, Beate; Zaiac, Michael; Voltz-Girolt, Caroline; Pignatti, Francesco

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab

晚期尿路上皮癌患者(不适合接受顺铂治疗)接受一线恩福妥单抗单药治疗或联合帕博利珠单抗治疗的患者报告结局

Milowsky, Matthew I; O'Donnell, Peter H; Hoimes, Christopher J; Petrylak, Daniel P; Flaig, Thomas W; Moon, Helen H; Friedlander, Terence W; Mar, Nataliya; McKay, Rana R; Srinivas, Sandy; Gravis, Gwenaelle; Ramamurthy, Chethan; Bupathi, Manojkumar; Bracarda, Sergio; Wright, Phoebe; Hepp, Zsolt; Carret, Anne-Sophie; Yu, Yao; Dillon, Ryan; Kataria, Ritesh; Beaumont, Jennifer L; Purnajo, Intan; Rosenberg, Jonathan E

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

放射学无进展生存期和临床无进展生存期作为转移性激素敏感性前列腺癌男性患者总生存期的潜在替代指标

Halabi, Susan; Roy, Akash; Rydzewska, Larysa; Guo, Siyuan; Godolphin, Peter; Hussain, Maha; Tangen, Catherine; Thompson, Ian; Xie, Wanling; Carducci, Michael A; Smith, Matthew R; Morris, Michael J; Gravis, Gwenaelle; Dearnaley, David P; Verhagen, Paul; Goto, Takayuki; James, Nick; Buyse, Marc E; Tierney, Jayne F; Sweeney, Christopher

Reply to J.A. Garcia et al

回复 JA Garcia 等人

Halabi, Susan; Guo, Siyuan; Roy, Akash; Rydzewska, Larysa E; Godolphin, Peter; Hussain, Maha; Tangen, Catherine; Thompson, Ian; Xie, Wanling; Carducci, Michael A; Morris, Michael J; Smith, Matthew R; Gravis, Gwenaelle; Dearnaley, David P; Verhagen, Paul J; Goto, Takayuki J; James, Nick D; Buyse, Marc E; Tierney, Jayne F; Sweeney, Christopher J

A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1

一项针对既往接受过大量治疗的转移性去势抵抗性前列腺癌患者的阿贝西利信号探索性研究:CYCLONE 1 研究结果

Agarwal, Neeraj; Castellano, Daniel; Alonso-Gordoa, Teresa; Arranz Arija, Jose Angel; Colomba, Emeline; Gravis, Gwenaelle; Mourey, Loic; Oudard, Stephane; Fléchon, Aude; González, Macarena; Rey, Pablo M; Schweizer, Michael T; Gallardo, Enrique; Johnston, Erica; Balar, Arjun; Haddad, Nadine; Appiah, Adams K; Nacerddine, Karim; Piulats, José M

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma

肿瘤突变负荷和PD-L1与帕博利珠单抗联合或不联合化疗治疗晚期尿路上皮癌疗效的相关性

Fléchon, Aude; Morales-Barrera, Rafael; Powles, Thomas; Alva, Ajjai; Özgüroğlu, Mustafa; Csöszi, Tibor; Loriot, Yohann; Rodriguez-Vida, Alejo; Géczi, Lajos; Cheng, Susanna Y; Fradet, Yves; Oudard, Stéphane; Vulsteke, Christof; Gunduz, Seyda; Mamtani, Ronac; Yu, Evan Y; Montesa Pino, Alvaro; Anido, Urbano; Sendur, Mehmet A N; Gravis, Gwenaelle; Révész, János; Kostorov, Vladimir; Huillard, Olivier; Ma, Junshui; Rajasagi, Mohini; Vajdi, Amir; Lunceford, Jared; Cristescu, Razvan; Imai, Kentaro; Homet Moreno, Blanca; Matsubara, Nobuaki

Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone

针对去势抵抗性前列腺癌的 MET 抑制:利妥木单抗联合米托蒽醌和泼尼松的随机 II 期研究和生物标志物分析

Charles J Ryan, Mark Rosenthal, Siobhan Ng, Joshi Alumkal, Joel Picus, Gwenaëlle Gravis, Karim Fizazi, Frédéric Forget, Jean-Pascal Machiels, Sandy Srinivas, Min Zhu, Rui Tang, Kelly S Oliner, Yizhou Jiang, Elwyn Loh, Sarita Dubey, Winald R Gerritsen

A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)

一项针对实体瘤患者的 retifanlimab(一种人源化抗 PD-1 单克隆抗体)的 II 期研究 (POD1UM-203)

Di Giacomo, A M; Schenker, M; Medioni, J; Mandziuk, S; Majem, M; Gravis, G; Cornfeld, M; Ranganathan, S; Lou, S; Csoszi, T